Hispanolistic/E+ via Getty Images Investment Overview — Tango's Share Price Volatility Based On Competitor's Progress When I last covered Tango Therapeutics, Inc. (NASDAQ:TNGX) for Seeking Alpha, in January of this year, I gave the stock a “Buy” rating. I highlighted the fact that the Boston, Massachusetts-based biotech is one of only five companies to date — the others are Bristol Myers Squibb (BMY) (via its ~$5.8bn acquisition of Mirati Therapeutics), Amgen (AMGN), AstraZeneca (AZN), Johnson & Johnson ...

Central Press/Hulton Archive via Getty Images Written by Sam Kovacs Introduction Buy Low, Sell High, Get Paid To Wait. This is our investment philosophy. I make a point of repeating it as often as I can because it is so simple and elegant, that most investors overlook it. Einstein famously said that everything should be made as simple as possible, but not simpler. Well, this is as simple as it gets for investing. Of course, it brings up quite a few questions: what's low? What's high? Why get paid to wai ...

Summary of Amgen Inc. Conference Call Company Overview - **Company**: Amgen Inc. (NASDAQ: AMGN) - **Event**: Wells Fargo 2024 Healthcare Conference Call - **Date**: September 5, 2024 Key Points Industry and Company Mission - Amgen's mission is to serve patients by discovering, developing, manufacturing, and delivering innovative medicines for serious illnesses globally [6][7] Financial Performance - In Q2 2024, Amgen reported revenues of $8.4 billion, a 20% increase year-over-year, marking the highest quarterly revenues in the company's history [9] - Twelve products achieved double-digit sales growth in the same quarter [9] Product Pipeline and Growth Areas - Amgen has a strong long-term growth outlook across four therapeutic areas: general medicine, oncology, hematology, and rare diseases [7][22] - Key brands driving growth include Repatha, EVENITY, BLINCYTO, and TEZSPIRE, with Repatha and EVENITY growing 25% and 39% respectively in Q2 [10][12] - Significant milestones achieved in 2024 include: - Accelerated approval of IMDELLTRA for small cell lung cancer - Approval of BLINCYTO for frontline treatment of B-cell precursor acute lymphoblastic leukemia - Positive Phase III data for UPLIZNA in IgG4-related disease [8][9] Research and Development Focus - Amgen is prioritizing internal innovation, with a capital allocation strategy focused on R&D [20][21] - The company is excited about the upcoming Phase II data for MariTide, an antibody peptide conjugate targeting obesity and related conditions, expected by the end of 2024 [26][28] - Olpasiran, a small interfering RNA targeting Lp(a), is undergoing a Phase III trial to assess its impact on cardiovascular risk [35][36] Manufacturing and Capacity Expansion - Amgen is investing in manufacturing capabilities, with significant expansions in Ohio and North Carolina to support future product launches [55][58][59] - The company raised its capital expenditure guidance from $1.1 billion to $1.3 billion for the year, indicating a commitment to enhancing manufacturing capacity [59] Competitive Landscape and Market Position - UPLIZNA is positioned as a competitive treatment for myasthenia gravis, with a focus on eradicating CD19 positive B cells, which may offer advantages over existing therapies [49][50] - The company is leveraging its experience from the Repatha launch to maximize the potential of new products in the cardiovascular space [41][42] Future Outlook - Amgen is optimistic about its innovative pipeline and the potential impact of its therapies on patient care, emphasizing a patient-centric approach [24][60] - The company is committed to maintaining a strong focus on innovation and operational excellence to drive future growth [18][19] Additional Insights - The leadership team highlighted the importance of a collaborative and innovative culture within the company, which is crucial for advancing its research and development efforts [19] - The strategic focus on high-impact medicines and rigorous prioritization of projects is expected to enhance the company's growth trajectory [16][20]

A month has gone by since the last earnings report for Amgen (AMGN) . Shares have added about 5.8% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Amgen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q2 Earnings & Sales BeatAmgen’s second-quarter results were s ...

Amgen (AMGN) stock has risen 19.6% in the past six months compared with an increase of 12.4% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.AMGN Stock Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe stock has also been consistently trading above its 50-day and 200-day moving averages since early August.One of the key reasons for the recent stock price outperformance has been its strong second-quarter results, as ...

Company and Industry Overview * **Company**: Amgen Inc. (NASDAQ: AMGN) * **Industry**: Biopharmaceuticals * **Focus**: Developing innovative medicines for unmet medical needs in general medicine, oncology, inflammation, and rare diseases. Key Points Business Performance * **General Medicine**: Repatha and EVENITY continue to grow strongly, with Repatha up 25% in Q2 2024 and EVENITY up 40%. * **Oncology**: Oncology portfolio up 12% on the quarter, driven by strong performance across multiple medicines. * **Inflammation**: TEZSPIRE grew 75% in Q2 2024, with potential to be a game-changing medicine. * **Rare Diseases**: TEPEZZA, KRYSTEXXA, and UPLIZNA are performing well, with UPLIZNA showing spectacular data in IgG4-related disease. * **Pipeline**: Strong pipeline with visible molecules in each area, including bispecifics, novel biologics, and next-generation assets. Strategy and Growth * **Innovation**: Focus on innovation and addressing unmet medical needs. * **International Growth**: Well-established globally, with strong growth in Asia and other international markets. * **Pipeline**: Exciting pipeline with multiple late-stage programs and next-generation assets. * **Biosimilars**: Developing biosimilars to augment existing products and expand market access. Policy and Regulatory * **Inflation Reduction Act (IRA)**: Concerns about the impact of IRA on innovation and investment in the industry. * **Policy Engagement**: Active engagement in Washington D.C. to ensure understanding of the biopharmaceutical industry and the impact of policies like IRA. Pipeline Details * **MariTide**: Next-generation obesity asset with a different mechanism of action and dosing advantage compared to existing treatments. * **Rocatinlimab**: Novel OX40 antibody for atopic dermatitis, prurigo nodularis, and respiratory diseases. * **Olpasiran**: Novel Lp(a) lowering therapy for patients at high risk of cardiovascular disease. * **AI**: Investing in AI to accelerate drug discovery and development. Other Important Points * **Horizon Integration**: Integration of Horizon Therapeutics is progressing well, with a strong fit between teams and exciting potential for future growth. * **Puerto Rico Tax Litigation**: High confidence in a favorable outcome in the tax court later in the year.

THOUSAND OAKS, Calif., Aug. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, Sept. 5, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, i ...

THOUSAND OAKS, Calif., Aug. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Sept. 4, 2024. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments ...

Amgen HQ in Thousand Oaks, CA JHVEPhoto Earlier this month, Wells Fargo cut its rating on Amgen (NASDAQ:AMGN), stating that success of its GLP-1 candidate MariTide was already priced into the shares. However, trading at 16.6x next year's earnings, the stock seems fairly valued despite 27% price appreciation over the past year. Existing product lines provide a strong foundation for the Amgen's valuation, while a successful conclusion to MariTide's crucial phase II study may provide a bullish catalyst later t ...

PeopleImages Since the publication of my last article, "Amgen: You Haven't Seen Anything Yet," Amgen's (NASDAQ:AMGN) share price has risen by more than 20%, thanks in part to increased speculative interest ahead of upcoming clinical results for MariTide in treating patients suffering from obesity, strong sales of its oncology and osteoporosis franchises, as well as medicines acquired in the Horizon Therapeutics deal. What will be presented in this article? I will discuss in detail several topics that ar ...